
    
      OBJECTIVES:

        -  Determine the effect of rituximab and high-dose cyclophosphamide on the growth of
           myeloma stem cells in patients with high-risk, refractory, or relapsed multiple myeloma.

      OUTLINE: Patients receive rituximab IV on days -10 and -7; once weekly for 4 weeks (after
      completion of high-dose cyclophosphamide); and then once in months 3, 6, 9, and 12. Patients
      also receive high-dose cyclophosphamide on days -3 to 0.

      PROJECTED ACCRUAL: Not specified.
    
  